16.30

3.36% +0.53

After Hours: 15.9499 -0.3501 -2.15%

Celcuity Inc (CELC)

Overview News Price History Option Chain Discussions Forecast

Celcuity Inc stock is currently priced at $16.30, with a 24-hour trading volume of 354.26K. It has seen a +3.36% increased in the last 24 hours and a -21.56% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $15.91 pivot point. If it approaches the $16.46 resistance level, significant changes may occur.

Previous Close:

$15.77

Open:

$15.84

24h Volume:

354.26K

Market Cap:

$496.39M

Revenue:

Net Income/Loss:

$-63.78M

P/E Ratio:

-6.1509

EPS:

-2.65

Net Cash Flow:

$-53.91M

1W Performance:

-3.78%

1M Performance:

-21.56%

6M Performance:

+61.71%

1Y Performance:

+68.04%

1D Range:

$15.50

$16.40

52W Range:

$8.389

$22.19

Celcuity Inc Stock (CELC) Company Profile

Name

Celcuity Inc

Sector

Healthcare (1197)

Industry

Biotechnology (685)

Phone

763-392-0767

Address

16305 – 36th Avenue North, Suite 450, Minneapolis, MN

Employee

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

CELC's Discussions on Twitter

Celcuity Inc Stock (CELC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-08-21	Initiated	Canaccord Genuity	Buy
Sep-07-21	Initiated	Jefferies	Buy
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy
Jan-28-21	Reiterated	H.C. Wainwright	Buy
Dec-24-20	Reiterated	H.C. Wainwright	Buy
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy

View All

Celcuity Inc Stock (CELC) Latest News

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

GlobeNewswire Inc.

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire Inc.

Why Celcuity (CELC) Might Surprise This Earnings Season

Zacks Investment Research

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

GlobeNewswire Inc.

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

GlobeNewswire Inc.

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

GlobeNewswire Inc.

Celcuity Inc Stock (CELC) Financials Data

Celcuity Inc (CELC) Net Income 2024

CELC net income (TTM) was -$63.78 million for the quarter ending December 31, 2023, a -57.99% decrease year-over-year.

Celcuity Inc (CELC) Cash Flow 2024

CELC recorded a free cash flow (TTM) of -$53.91 million for the quarter ending December 31, 2023, a -49.06% decrease year-over-year.

Celcuity Inc (CELC) Earnings per Share 2024

CELC earnings per share (TTM) was -$2.68 for the quarter ending December 31, 2023, a -1.52% decline year-over-year.

Celcuity Inc Stock (CELC) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Buller Richard E	Director	Feb 21 '24	Sale	14.15	350	4,952	8,081
Buller Richard E	Director	Dec 20 '23	Sale	14.37	350	5,030	8,431
Dalvey David	Director	Dec 15 '23	Sale	14.57	2,940	42,847	225,000
Dalvey David	Director	Dec 14 '23	Sale	14.75	5,000	73,752	227,940
Dalvey David	Director	Dec 13 '23	Sale	14.50	5,000	72,500	232,940
Dalvey David	Director	Dec 12 '23	Sale	14.61	2,060	30,089	237,940
Dalvey David	Director	Dec 08 '23	Sale	15.00	5,000	75,000	240,000
Dalvey David	Director	Dec 07 '23	Sale	14.85	5,000	74,250	245,000
Furcht Leo	Director	Nov 28 '23	Option Exercise	1.60	250	400	10,500
Buller Richard E	Director	Oct 25 '23	Sale	10.23	350	3,580	8,781

Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.